Limitations, agreements, and source contact

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer · Source last updated 2022-01-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

true

point Of Contact

email

ClinicalTrials@Myovant.com

organization

Myovant Sciences GmbH

phone

650-278-8743

title

Clinical Trials at Myovant

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice